nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

26.02.2019 | Original Article

Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume

verfasst von: Luca Ceriani, Lisa Milan, Peter W. M. Johnson, Maurizio Martelli, Stefano Presilla, Luca Giovanella, Emanuele Zucca

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study assessed the performance of four different methods for the estimation of metabolic tumour volume (MTV) in primary mediastinal B cell lymphoma (PMBCL).

Method

MTV was estimated using either a region growing automatic software program (RG) or a fixed threshold (FT) segmentation algorithm with the three most common cut-offs proposed in the literature (i.e., 25% and 41% of the SUVmax and SUV value ≥2.5). We compared these four methods using phantoms that simulated different set-ups of the main imaging characteristics of PMBCL (volume, shape, 18-FDG uptake and intra-lesion distribution) and assessed their performance in 103 PMBCL patients enrolled in the International Extranodal Lymphoma Study Group-26 (IELSG-26) study.

Results

There was good correlation between MTV values estimated in vitro and in vivo using the different methods. The 25% FT cut-off (FT25%) provided the most accurate MTV evaluation in the phantoms. The cut-off at SUV 2.5 (FT2.5) resulted in MTV overestimation that particularly increased with high SUV values. The 41% cut-off (FT41%) showed MTV underestimation that was more evident when there were high levels of heterogeneity in tracer distribution. Shape of the lesion did not affect MTV computation. The RG algorithm provided a systematic slight MTV underestimation without significant changes due to lesion characteristics. We observed analogous trends for the MTV estimation in patients, with very different derived thresholds for the four methods. Optimal cut-offs for predicting progression-free survival (PFS) ranged from 213 to 831 ml. All methods predicted PFS with similar negative predictive values (94–95%) but different positive predictive values (23–45%).

Conclusions

The different methods result in significantly different MTV cut-off values. All allow risk stratification in PMBCL, but FT25% showed the best capacity to predict disease progression in the patient cohort and provided the best accuracy in the phantom model.

Nur mit Berechtigung zugänglich

Boleti E, Johnson PW. Primary mediastinal B-cell lymphoma. Hematol Oncol. 2007;25:157–63. https://doi.org/10.1002/hon.818.CrossRefPubMed

Gaulard P, Harris NL, Pileri SA, Kutock JL, Stein H, Kovrigina AM, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 250–3.

Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659–69. https://doi.org/10.1182/blood-2011-05-326538.CrossRefPubMed

Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood. 2003;102:3871–9. https://doi.org/10.1182/blood-2003-06-1841.CrossRefPubMed

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62. https://doi.org/10.1084/jem.20031074.CrossRefPubMedPubMedCentral

Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Am Soc Hematol Educ Program. 2008;2008:349–58. https://doi.org/10.1182/asheducation-2008.1.349.CrossRef

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16. https://doi.org/10.1056/NEJMoa1214561. CrossRefPubMedPubMedCentral

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the international extranodal lymphoma study group IELSG-26 study. J Clin Oncol. 2014;32:1769–75. https://doi.org/10.1200/jco.2013.51.7524.CrossRefPubMed

Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:1329–36. https://doi.org/10.1080/10428190802108870.CrossRefPubMed

10.

Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372–6. https://doi.org/10.1038/sj.bjc.6601460.CrossRefPubMedPubMedCentral

11.

Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–54. https://doi.org/10.1200/JCO.2010.32.5225.CrossRefPubMed

12.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed

13.

Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90. https://doi.org/10.2967/jnumed.112.110890.CrossRefPubMed

14.

Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20. https://doi.org/10.1007/s00259-013-2435-6.CrossRefPubMed

15.

Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33. https://doi.org/10.2967/jnumed.108.057703.CrossRefPubMed

16.

Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. https://doi.org/10.1016/s0140-6736(10)62175-7.CrossRefPubMed

17.

Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290–301. https://doi.org/10.1007/s00259-012-2280-z.CrossRefPubMed

18.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829–35. https://doi.org/10.2967/jnumed.112.106500.CrossRefPubMed

19.

Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321–9. https://doi.org/10.1007/s00259-013-2443-6.CrossRefPubMed

20.

Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703. https://doi.org/10.1007/s00277-011-1357-2.CrossRefPubMed

21.

Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92:471–9. https://doi.org/10.1007/s00277-012-1640-x.CrossRefPubMed

22.

Manohar K, Mittal BR, Bhattacharya A, Malhotra P, Varma S. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma. Nucl Med Commun. 2012;33:974–81. https://doi.org/10.1097/MNM.0b013e32835673ec.CrossRefPubMed

23.

Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D, et al. F-18 FDG PET/CT quantisation parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014. https://doi.org/10.1111/ejh.12268.

24.

Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272–81.PubMedPubMedCentral

25.

Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:494–504. https://doi.org/10.1007/s00259-009-1275-x.CrossRefPubMed

26.

Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618–26. https://doi.org/10.1200/jco.2016.66.9440.CrossRefPubMed

27.

Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719–24. https://doi.org/10.1093/annonc/mdw011.CrossRefPubMed

28.

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43. https://doi.org/10.1007/s00259-014-2783-x.CrossRefPubMed

29.

Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22. https://doi.org/10.1007/s00259-014-2705-y.CrossRefPubMed

30.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

31.

Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22. https://doi.org/10.1007/s00259-014-2822-7.CrossRefPubMed

32.

Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, Moller H, Smith D, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:1142–54. https://doi.org/10.1007/s00259-018-3953-z.CrossRefPubMedPubMedCentral

33.

Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–6. https://doi.org/10.1182/blood-2014-12-616474.CrossRefPubMed

34.

Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018;132:179–86. https://doi.org/10.1182/blood-2018-01-826958.CrossRefPubMed

35.

Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed

36.

Firouzian A, Kelly MD, Declerck JM. Insight on automated lesion delineation methods for PET data. EJNMMI Res. 2014;4:69. https://doi.org/10.1186/s13550-014-0069-8.CrossRefPubMedPubMedCentral

37.

Pratt WK. Image segmentation. Digital image processing: PIKS scientific inside, fourth edition. Wiley; 2007.

38.

Vorwerk H, Beckmann G, Bremer M, Degen M, Dietl B, Fietkau R, et al. The delineation of target volumes for radiotherapy of lung cancer patients. Radiother Oncol. 2009;91:455–60. https://doi.org/10.1016/j.radonc.2009.03.014.CrossRefPubMed

39.

Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965–70. https://doi.org/10.1093/biomet/92.4.965.CrossRef

40.

Posada D, Buckley TR. Model selection and model averaging in Phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst Biol. 2004;53:793–808. https://doi.org/10.1080/10635150490522304.CrossRefPubMed

41.

Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ (Clin Res ed). 1994;309:102.CrossRef

42.

Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60. https://doi.org/10.1080/10428190903040048.CrossRefPubMed

Titel: Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume
verfasst von: Luca Ceriani
Lisa Milan
Peter W. M. Johnson
Maurizio Martelli
Stefano Presilla
Luca Giovanella
Emanuele Zucca
Publikationsdatum: 26.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04286-8

Springer Medizin

Abstract

Purpose

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis

Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma

FDG atrial uptake is associated with an increased prevalence of stroke in patients with atrial fibrillation

Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma

The validity of 18F-GE180 as a TSPO imaging agent

Heart rate reserve during pharmacological stress is a significant negative predictor of impaired coronary flow reserve in women